1. Comparison of the Clinical Features of Hepatitis A in People Living with HIV between Pandemics in 1999-2000 and 2017-2018 in the Metropolitan Area of Japan.
- Author
-
Koga M, Lim LA, Ogishi M, Satoh H, Kikuchi T, Adachi E, Sugiyama R, Kiyohara T, Suzuki R, Muramatsu M, Koibuchi T, Tsutsumi T, and Yotsuyanagi H
- Subjects
- Adult, Anti-Retroviral Agents adverse effects, Anti-Retroviral Agents therapeutic use, CD4 Lymphocyte Count, CD8-Positive T-Lymphocytes, Cities epidemiology, Coinfection virology, Genome, Viral, HIV Infections virology, Hepatitis A immunology, Hepatitis A Antibodies blood, Hepatitis A virus genetics, Hepatitis A virus immunology, Homosexuality, Male, Humans, Japan epidemiology, Liver drug effects, Liver pathology, Liver virology, Male, Middle Aged, Sexual and Gender Minorities, HIV Infections epidemiology, Hepatitis A epidemiology
- Abstract
Since 2017, hepatitis A virus (HAV) infection has been an epidemic among men who have sex with men (MSM) in Japan. We have come across 11 MSM patients with hepatitis A who were also infected with HIV. In 1999-2000, we came across 5 HIV-infected patients with hepatitis A. Since the conditions of current HIV-infected patients have changed owing to the recent progress in anti-HIV therapies, we compared clinical features of hepatitis A between patients in 2017-2018 and those in 1999-2000. By comparing the background characteristics of the patients, we found that the CD4/CD8 ratio was significantly higher in the 2017-2018 group. After the onset of hepatitis, peak levels of hepatic transaminases were found to be higher in the 2017-2018 group, suggesting severe hepatocellular damage. In contrast, neither the peak level of total bilirubin nor the nadir of prothrombin time was significantly different among the 2 groups. We also analyzed the HAV genome derived from some of the recently infected patients, and found that the HAV strains were almost the same among these patients; slight differences were observed from the previously identified strain. Thus, we concluded that the recovery of immunity by recent anti-HIV therapies may result in more severe hepatocellular damages and differences in clinical features.
- Published
- 2020
- Full Text
- View/download PDF